Ambara Joto Venture
The company will be entering into a joint venture with the government of Zambia. In this JV, Akums will be wielding the majority stake of 51%, with the rest lying with the state of Zambia. Both the entities in the JV, as per Akums, will jointly invest in the facility and commercial operations in the ratio of their respective shareholdings.The facility is expected to be completed by 2028 and will look to manufacture general oral solids, liquids, and injectables, as well as beta-lactam products.
Future Expansion Plans
In addition, Akum also said that the Zambian government shall purchase medicines from the JV having a minimum aggregate value of $50 million over 2 years in 2026 and 2027, i.e., USD 25 million annually, which will be manufactured and supplied from Akum’s and/or its subsidiaries’ facilities in India.Laying out the objectives of the project, the company added that it aims to support the government’s national health programmes and enhance local production capabilities.
Furthermore, the company also added that the said facility also plans to export to neighbouring countries in the southern half of the African continent, including Botswana, Malawi, Mozambique, Namibia, Tanzania, Zimbabwe, etc.
Q1 Results
When it comes to the company’s Q1 results, the company recorded a net profit of ₹63.48 crore in the quarter ended June 2025. This was higher than the previous cycle’s 60.17 crore, marking a 5.50% increase in profits.
The company’s sales rose 0.48% to ₹1024.03 crore in the quarter ended June 2025.
The company shares closed in red on August 22, with a decline of ₹0.90, or 0.19%. In the past month of trade, the pharma company shares have seen a decline of ₹60.05, or 11.10%. The current stock price is at ₹480.90 per piece.
Also Read: Jerome Powell signals Fed may cut rates soon even as inflation risks remain
